Platelet Inhibition via Epigenome Editing for Long-Term Thrombosis Prevention with a Single Treatment
The Shadow of Thrombosis and a New Hope
Thrombosis is a leading cause of cardiovascular and cerebrovascular disease, and the continual production of platelets poses a major challenge. Existing drugs provide only transient inhibition, making long‑term prevention difficult.
Epigenome Editing for Permanent Reprogramming of HSCs
The research team delivered an RNA‑based DNA methylation editor to HSCs, achieving sustained silencing of a target gene. This silencing persisted even as the cells self‑renewed and differentiated into platelets.
Reversible Developmental Switch
Importantly, using the same editor to remove methylation at the target locus reactivates the gene, providing a reversible on/off control of the therapeutic effect.
Future Significance and Outlook
If translated to the clinic, a single cell therapy could permanently reduce thrombosis risk. Personalized epigenome‑editing technologies may open a new era in the prevention of hematologic disorders.
Thrombosis remains a major cause of cardiovascular and cerebrovascular diseases, driven in large part by platelet activation and aggregation. Because platelets are continuously produced from hematopoietic stem cells (HSCs), durable reprogramming of HSC output offers a unique opportunity for a one-time antithrombotic intervention. Here, we show that DNA methylation-based epigenome editors delivered transiently as RNA result in stable, heritable gene silencing in primary human HSCs that persists through long-term self-renewal and megakaryocytic differentiation, while remaining reversible through targeted demethylation. Targeting the platelet integrin β3 (
This study addresses the lack of strategies to fundamentally suppress the excessive platelet activation that drives thrombosis. By enabling long‑term thrombosis prevention with a single cell therapy, it could markedly reduce the risk of myocardial infarction and stroke in everyday life.